In sorafenib-responsive HCC cells, YAP/TAZ and ATF4 cannot be activated and are not localized to the nucleus, thus they do not activate the expression of SLC7A11 or increase intracellular glutathione levels. Here, SLC7A11 is linked to hepatocellular carcinoma.